Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, has announced its upcoming participation in a virtual event. CEO Marcio Souza will engage in a fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025 at 10:00 AM EST.
Praxis Precision Medicines (NASDAQ: PRAX), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie per disturbi del sistema nervoso centrale, ha annunciato la sua prossima partecipazione a un evento virtuale. Il CEO Marcio Souza parteciperà a una conversazione informale moderata dall'analista di Truist Securities Joon Lee il 5 agosto 2025 alle 10:00 EST.
Praxis Precision Medicines (NASDAQ: PRAX), una compañía biofarmacéutica en etapa clínica enfocada en desarrollar terapias para trastornos del sistema nervioso central, ha anunciado su próxima participación en un evento virtual. El CEO Marcio Souza participará en una charla informal moderada por el analista de Truist Securities Joon Lee el 5 de agosto de 2025 a las 10:00 AM EST.
Praxis Precision Medicines (NASDAQ: PRAX)는 중추신경계 질환 치료제 개발에 주력하는 임상 단계 바이오제약 회사로, 곧 개최되는 가상 행사에 참여할 예정임을 발표했습니다. CEO Marcio Souza는 Truist Securities의 애널리스트 Joon Lee가 진행하는 대화에 2025년 8월 5일 오전 10시 EST에 참여할 예정입니다.
Praxis Precision Medicines (NASDAQ : PRAX), une société biopharmaceutique en phase clinique spécialisée dans le développement de thérapies pour les troubles du système nerveux central, a annoncé sa prochaine participation à un événement virtuel. Le PDG Marcio Souza participera à une discussion informelle animée par l’analyste de Truist Securities Joon Lee le 5 août 2025 à 10h00 EST.
Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für Erkrankungen des zentralen Nervensystems konzentriert, hat seine bevorstehende Teilnahme an einer virtuellen Veranstaltung angekündigt. CEO Marcio Souza wird an einem Gespräch mit Truist Securities Analyst Joon Lee am 5. August 2025 um 10:00 Uhr EST teilnehmen.
- None.
- None.
BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025 at 10:00amEST.
The registration link can be found here.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
When is the Praxis Precision Medicines (PRAX) fireside chat scheduled for?
Who will represent Praxis Precision Medicines at the Truist Securities fireside chat?
What is Praxis Precision Medicines' (PRAX) main focus area?
Who is hosting the PRAX fireside chat?
